Granzyme B Cleaves Multiple Herpes Simplex Virus 1 and Varicella-Zoster Virus (VZV) Gene Products, and VZV ORF4 Inhibits Natural Killer Cell Cytotoxicity.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 01 08 2019
accepted: 19 08 2019
pubmed: 30 8 2019
medline: 21 7 2020
entrez: 30 8 2019
Statut: epublish

Résumé

Immune regulation of alphaherpesvirus latency and reactivation is critical for the control of virus pathogenesis. This is evident for herpes simplex virus 1 (HSV-1), where cytotoxic T lymphocytes (CTLs) prevent viral reactivation independent of apoptosis induction. This inhibition of HSV-1 reactivation has been attributed to granzyme B cleavage of HSV infected cell protein 4 (ICP4); however, it is unknown whether granzyme B cleavage of ICP4 can directly protect cells from CTL cytotoxicity. Varicella zoster virus (VZV) is closely related to HSV-1; however, it is unknown whether VZV proteins contain granzyme B cleavage sites. Natural killer (NK) cells play a central role in VZV and HSV-1 pathogenesis and, like CTLs, utilize granzyme B to kill virally infected target cells. However, whether alphaherpesvirus granzyme B cleavage sites could modulate NK cell-mediated cytotoxicity has yet to be established. This study aimed to identify novel HSV-1 and VZV gene products with granzyme B cleavage sites and assess whether they could protect cells from NK cell-mediated cytotoxicity. We have demonstrated that HSV ICP27, VZV open reading frame 62 (ORF62), and VZV ORF4 are cleaved by granzyme B. However, in an NK cell cytotoxicity assay, only VZV ORF4 conferred protection from NK cell-mediated cytotoxicity. The granzyme B cleavage site in ORF4 was identified via site-directed mutagenesis and, surprisingly, the mutation of this cleavage site did not alter the ability of ORF4 to modulate NK cell cytotoxicity, suggesting that ORF4 has a novel immunoevasive function that is independent from the granzyme B cleavage site.

Identifiants

pubmed: 31462576
pii: JVI.01140-19
doi: 10.1128/JVI.01140-19
pmc: PMC6819919
pii:
doi:

Substances chimiques

Immediate-Early Proteins 0
Viral Proteins 0
herpes simplex virus, type 1 protein ICP4 0
Granzymes EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3496-501
pubmed: 17360672
J Virol. 2005 Jun;79(11):6969-75
pubmed: 15890936
Front Immunol. 2014 Mar 07;5:80
pubmed: 24639676
J Virol. 2014 Mar;88(5):2704-16
pubmed: 24352459
Immunity. 2001 Jun;14(6):751-61
pubmed: 11420045
Cell Death Dis. 2017 Apr 13;8(4):e2749
pubmed: 28406478
J Virol. 2010 Sep;84(18):9240-53
pubmed: 20631144
J Virol. 2008 Apr;82(7):3538-45
pubmed: 18216091
J Exp Med. 2000 Nov 20;192(10):1403-14
pubmed: 11085743
J Virol. 2015 Aug;89(15):7932-43
pubmed: 25995251
Nat Rev Microbiol. 2014 Mar;12(3):197-210
pubmed: 24509782
Herpesviridae. 2012 Jun 12;3(1):5
pubmed: 22691604
J Virol. 2018 May 29;92(12):
pubmed: 29593042
J Virol. 2018 May 14;92(11):
pubmed: 29540598
PLoS Pathog. 2018 Apr 30;14(4):e1006999
pubmed: 29709039
EMBO J. 2007 Apr 18;26(8):2148-57
pubmed: 17363894
Future Microbiol. 2011 Nov;6(11):1261-77
pubmed: 22082288
Immunol Rev. 2010 May;235(1):105-16
pubmed: 20536558
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W208-13
pubmed: 15980455
J Virol. 2010 Sep;84(17):8861-70
pubmed: 20573825
J Exp Med. 2000 May 1;191(9):1459-66
pubmed: 10790421
Science. 2008 Oct 10;322(5899):268-71
pubmed: 18845757
J Biol Chem. 2003 Sep 26;278(39):38068-75
pubmed: 12855699
Cell. 1998 Aug 21;94(4):491-501
pubmed: 9727492
Virology. 1992 Nov;191(1):346-54
pubmed: 1329324
Genes Dev. 1998 Mar 15;12(6):868-79
pubmed: 9512520

Auteurs

Chelsea Gerada (C)

Discipline of Infectious Diseases and Immunology, The University of Sydney, Camperdown, New South Wales, Australia.

Megan Steain (M)

Discipline of Infectious Diseases and Immunology, The University of Sydney, Camperdown, New South Wales, Australia.

Tessa Mollie Campbell (TM)

Discipline of Infectious Diseases and Immunology, The University of Sydney, Camperdown, New South Wales, Australia.

Brian McSharry (B)

Discipline of Infectious Diseases and Immunology, The University of Sydney, Camperdown, New South Wales, Australia.

Barry Slobedman (B)

Discipline of Infectious Diseases and Immunology, The University of Sydney, Camperdown, New South Wales, Australia.

Allison Abendroth (A)

Discipline of Infectious Diseases and Immunology, The University of Sydney, Camperdown, New South Wales, Australia allison.abendroth@sydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH